查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1865472

可近性診斷和篩檢盒市場預測至2032年：按產品、樣本類型、分銷管道、應用、最終用戶和地區分類的全球分析

Accessible Diagnostics & Screening Kits Market Forecasts to 2032 - Global Analysis By Product, Sample Type, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球可及診斷和篩檢試劑盒市場預計到 2025 年將達到 3,104.1 億美元，到 2032 年將達到 5,459.4 億美元，預測期內複合年成長率為 8.4%。

便捷的診斷和篩檢盒是創新醫療工具，旨在提供簡單、低成本且可靠的疾病早期檢測方法。這些試劑盒採用簡化的攜帶式或居家檢測技術，提高了診斷的便利性和整體性，並減少了對複雜醫療基礎設施的依賴。透過改善醫療服務的可近性，並支持服務不足和偏遠地區的預防性篩檢，這些試劑盒顯著促進了及時醫療干預和更佳的人群健康管理。

人們對分散式醫療保健的興趣日益濃厚

數位健康平台、攜帶式診斷工具和人工智慧分析系統的進步使得快速且準確的自我檢測成為可能。這些技術幫助人們無需前往傳統醫療機構即可及時獲得健康評估，尤其是在醫療資源匱乏的地區。隨著遠端醫療和連線健診系統的擴展，診斷試劑盒正日益融入虛擬諮詢中。政府和私部門主導的居家照護推廣計畫正在加速已開發經濟體和新興經濟體的普及。隨著醫療模式向以患者為中心的模式轉變，分散式診斷在提高醫療服務的可近性、可負擔性和預防性醫療保健效果方面發揮關鍵作用。

基礎設施不足

在許多中低收入地區，實驗室支援有限、供應鏈不穩定以及冷藏保管能力不足阻礙了可靠檢測結果的取得。網路連線不良和數位素養缺乏也限制了依賴即時數據共用的連網診斷平台的有效性。此外，監管分散和缺乏標準化檢測通訊協定也給製造商和醫療服務提供者帶來了挑戰。新興經濟體在確保公平分配和檢測後追蹤方面面臨特殊的挑戰。

平台技術進步

人工智慧驅動的分析、醫療物聯網 (IoMT) 和行動平台的融合正在革新就地檢驗和個人化診斷。雲端連接設備實現了患者、臨床醫生和實驗室之間的無縫數據共用，從而改善了臨床決策和疾病早期發現。實驗室晶片和生物感測器技術的進步正在降低檢測時間和成本，同時提高檢測準確性。各公司越來越關注互通性和支持持續健康監測的數位健康生態系統。隨著數位轉型加速，平台技術將成為全球醫療保健系統中擴充性、高效且易於獲取的診斷解決方案的基礎。

過度診斷和過度使用檢測的風險

家用和自測試劑盒的快速普及帶來了過度診斷和過度檢測的潛在風險，這可能導致不必要的焦慮和醫療干預。在缺乏專家指導的情況下，人們可以輕易獲得多種檢測選擇，這可能導致結果誤讀和不必要的治療。缺乏明確的自測後追蹤臨床指引加劇了這個問題。如果管理不善，來自連網裝置的數據也會增加假陽性和不準確讀數。為了降低這些風險，開發人員正在優先考慮在診斷系統中整合人工智慧檢驗工具、數據準確性演算法和用戶教育。

新冠疫情的影響：

新冠疫情大大推動了可近性診斷和篩檢盒市場的發展，引發了對快速居家檢測解決方案前所未有的需求激增。各國政府和衛生組織擴大了緊急使用授權範圍，加速了新型診斷技術的市場化。供應鏈中斷雖然帶來了初期挑戰，但最終促成了更本地化的生產和更多元化的來源。疫情過後，這些發展為可近性診斷技術的持續應用奠定了基礎，使其成為建立穩健醫療衛生基礎設施的基石。

預計在預測期內，自測檢測套組細分市場將佔據最大的市場佔有率。

由於消費者越來越傾向於便利、保護隱私且經濟實惠的健康監測解決方案，預計在預測期內，自測檢測套組細分市場將佔據最大的市場佔有率。人工智慧驅動的結果解讀、智慧型手機整合和即時數位報告等創新技術正在拓展其在各類疾病中的應用範圍。各公司正致力於開發多分析物平台，以便在單一裝置上檢測多種疾病。旨在推廣早期檢測和預防保健的公共宣傳宣傳活動也在推動市場滲透。電子商務和藥房分銷管道的擴充性正在提高都市區地區的可及性。

預計在預測期內，住宅用戶細分市場將實現最高的複合年成長率。

預計在預測期內，居家用戶群將實現最高成長率，這主要得益於遠距醫療管理和遠端醫療整合的日益普及。穿戴式生物辨識感測器、應用程式連接的診斷試劑盒和人工智慧健康助理等產品的廣泛應用，使得個人能夠自主進行定期健康評估。消費者對健康追蹤、預防性篩檢和慢性病管理的日益關注，正在擴大居家檢測的使用者群體。各公司正致力於開發直覺的設計和數位化平台，以簡化與醫療服務提供者的資料共用和使用。疫情引發的人們轉向自我護理和虛擬醫療服務的行為轉變，進一步推動了這個趨勢。

佔比最大的地區：

由於人口快速成長、醫療保健數位化不斷提高以及政府的大力支持，亞太地區預計將在預測期內佔據最大的市場佔有率。印度、中國和日本等國家在採用攜帶式和人工智慧診斷技術方面處於主導地位。電子健康平台的擴展和在地化生產的努力提高了篩檢盒的可及性和可負擔性。區域各國政府正致力於透過公私合營和行動醫療計畫來促進農村地區的醫療保健服務。不斷壯大的中產階級人口和日益增強的預防保健意識也是成長要素。

預計年複合成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於技術創新、強力的監管支持以及消費者意識的不斷提高。美國和加拿大在人工智慧整合診斷系統、遠端檢測平台和互聯醫療生態系統的應用方面處於主導地位。大量的研發投入，加上關鍵產業參與者的存在，正在加速產品創新和商業化進程。科技公司、醫療服務提供者和診斷設備製造商之間的策略聯盟正在提升互通性和用戶參與度。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球可近性診斷與篩檢試劑盒市場（依產品分類）

  • 自測檢測套組
    • 妊娠測試
    • 血糖監測
    • 新冠病毒快速檢測
    • 愛滋病毒/性傳染感染檢測
  • 實驗室篩檢盒
    • 分子診斷試劑盒
    • 免疫檢測盒
    • 基因篩檢組合
  • 照護現場（PoC）設備
    • 血液分析儀
    • 尿液分析儀
    • 移動診斷單元
  • 其他產品

6. 全球可及性診斷與篩檢試劑盒市場（依樣本類型分類）

  • 血
  • 尿
  • 唾液
  • 鼻咽拭子
  • 凳子

7. 全球可及診斷與篩檢試劑盒市場（按分銷管道分類）

  • 直接面對消費者（DTC）
  • 電子商務平台
  • 向機構投資人銷售
  • 零售藥房
  • 政府採購

8. 全球可近性診斷與篩檢試劑盒市場（按應用分類）

  • 感染疾病檢測
  • 慢性病監測
  • 癌症篩檢
  • 基因和產前檢測
  • 生活方式和健康監測
  • 其他用途

9. 全球可及診斷與篩檢試劑盒市場（依最終用戶分類）

  • 醫院和診所
  • 診斷實驗室
  • 家庭用戶
  • 藥局/零售連鎖店
  • 非政府組織和公共衛生項目
  • 其他最終用戶

10. 全球可近性診斷與篩檢試劑盒市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Siemens Healthineers
  • Agappe Diagnostics
  • GE HealthCare
  • PerkinElmer
  • Roche Diagnostics
  • Agilent Technologies
  • Danaher Corporation
  • Hologic, Inc.
  • Abbott Laboratories
  • bioMerieux
  • Thermo Fisher Scientific
  • Quest Diagnostics
  • Bio-Rad Laboratories
  • Becton, Dickinson and Company（BD）
  • QuidelOrtho Corporation
Product Code: SMRC32072

According to Stratistics MRC, the Global Accessible Diagnostics & Screening Kits Market is accounted for $310.41 billion in 2025 and is expected to reach $545.94 billion by 2032 growing at a CAGR of 8.4% during the forecast period. Accessible Diagnostics & Screening Kits are innovative medical tools created to provide easy, low-cost, and reliable testing for early disease detection. They use simplified, portable, or at-home technologies to make diagnostics more convenient and inclusive, reducing dependence on advanced medical infrastructure. By improving healthcare accessibility and supporting preventive screening in underserved or remote regions, these kits contribute significantly to timely medical intervention and better population health management.

Market Dynamics:

Driver:

Increased focus on decentralized healthcare

Advancements in digital health platforms, portable diagnostic tools, and AI-based interpretation systems are facilitating rapid and accurate self-testing. These technologies empower individuals, especially in underserved areas, to access timely health assessments without visiting traditional healthcare centers. The expansion of telemedicine and connected health ecosystems is further integrating diagnostic kits into virtual consultations. Government and private initiatives promoting home-based care are accelerating adoption across both developed and emerging economies. As the healthcare model shifts toward patient-centric approaches, decentralized diagnostics are playing a key role in improving accessibility, affordability, and preventive health outcomes.

Restraint:

Lack of infrastructure

In many low- and middle-income regions, limited laboratory support, inconsistent supply chains, and insufficient cold storage capabilities hinder reliable testing outcomes. Poor internet connectivity and digital literacy also restrict the effectiveness of connected diagnostic platforms that rely on real-time data sharing. Additionally, regulatory fragmentation and lack of standardized testing protocols create challenges for manufacturers and healthcare providers. Emerging economies face particular difficulties in ensuring equitable distribution and post-test follow-up care.

Opportunity:

Advancements in platform technology

Integration of AI-driven analytics, Internet of Medical Things (IoMT), and mobile-based platforms is revolutionizing point-of-care testing and personalized diagnostics. Cloud-connected devices now enable seamless data sharing between patients, clinicians, and laboratories, improving clinical decision-making and early disease detection. The development of lab-on-a-chip and biosensor technologies is enhancing test accuracy while reducing time and cost. Companies are increasingly focusing on interoperability and digital health ecosystems that support continuous health monitoring. As digital transformation accelerates, platform technologies will serve as the foundation for scalable, efficient, and accessible diagnostic solutions across global healthcare systems.

Threat:

Risk of overdiagnosis and overuse of tests

The rapid expansion of at-home and self-administered diagnostic kits poses the potential risk of overdiagnosis and test overuse, leading to unnecessary anxiety or medical interventions. Easy access to multiple testing options without professional supervision may result in misinterpretation of results and unwarranted treatments. The lack of clear clinical guidelines for follow-up care following self-testing compounds this issue. Data from connected devices, if mismanaged, can also increase false positives or inaccurate readings. To mitigate these risks, developers are emphasizing the integration of AI validation tools, data accuracy algorithms, and user education within diagnostic systems.

Covid-19 Impact:

The Covid-19 pandemic served as a major catalyst for the Accessible Diagnostics & Screening Kits Market, driving an unprecedented surge in demand for rapid and home-based testing solutions. Governments and health agencies expanded emergency authorizations, allowing faster market entry for new diagnostic technologies. Supply chain disruptions initially posed challenges, but they ultimately led to more localized production and diversification of suppliers. Post-pandemic, these developments have paved the way for sustained adoption of accessible diagnostics as a cornerstone of resilient healthcare infrastructure.

The self-testing kits segment is expected to be the largest during the forecast period

The self-testing kits segment is expected to account for the largest market share during the forecast period, due to growing consumer preference for convenient, private, and cost-effective health monitoring solutions. Innovations such as AI-powered result interpretation, smartphone integration, and real-time digital reporting are expanding their usability across diverse disease categories. Companies are focusing on multi-analyte platforms that allow users to test for multiple conditions using a single device. Public awareness campaigns promoting early detection and preventive care are also fueling market penetration. The scalability of e-commerce and pharmacy distribution channels enhances accessibility in both urban and rural regions.

The home users segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home users segment is predicted to witness the highest growth rate, due to increasing adoption of remote health management and telemedicine integration. The availability of wearable biosensors, app-connected diagnostic kits, and AI health assistants is empowering individuals to perform regular health assessments independently. Growing consumer focus on wellness tracking, preventive screening, and chronic disease management is expanding the home testing user base. Companies are investing in intuitive designs and digital platforms that simplify usage and data sharing with healthcare providers. The pandemic-driven behavioral shift toward self-care and virtual health services continues to sustain this trend.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rapid population growth, increasing healthcare digitization, and supportive government initiatives. Countries like India, China, and Japan are leading in the adoption of portable and AI-enabled diagnostic technologies. Expanding e-health platforms and local manufacturing initiatives are improving affordability and availability of screening kits. Regional governments are promoting healthcare access in rural areas through public-private partnerships and mobile health programs. The rise of middle-class populations and growing awareness of preventive care are also key growth drivers.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, propelled by technological innovation, robust regulatory support, and increasing consumer awareness. The U.S. and Canada are leading in the deployment of AI-integrated diagnostic systems, remote testing platforms, and connected medical ecosystems. High investment in R&D, combined with the presence of key industry players, is accelerating product innovation and commercialization. Strategic collaborations among tech firms, healthcare providers, and diagnostic manufacturers are enhancing interoperability and user engagement.

Key players in the market

Some of the key players in Accessible Diagnostics & Screening Kits Market include Siemens Healthineers, Agappe Diagnostics, GE HealthCare, PerkinElmer, Roche Diagnostics, Agilent Technologies, Danaher Corporation, Hologic, Inc., Abbott Laboratories, bioMerieux, Thermo Fisher Scientific, Quest Diagnostics, Bio-Rad Laboratories, Becton, Dickinson and Company (BD), QuidelOrtho Corporation.

Key Developments:

In October 2025, GE announced it has received CE mark for its Carevance(TM) patient monitor, advancing accessible and reliable care for more customers starting in Europe. Built on GE HealthCare's clinical excellence, Carevance offers a clinically reliable and cost-effective solution with validated parameters and an intuitive, efficient workflow that can help empower care teams to stay focused on their patients.

In July 2025, Covaris, a PerkinElmer company and pioneer in sample preparation technologies, and Hamilton Company announce a strategic partnership to co-market the truXTRAC(R) FFPE SMART Solution, powered by the Hamilton(R) Sonication STAR liquid handler. This joint solution offers a fully automated, walk-away workflow that delivers unmatched performance for nucleic acid extraction from FFPE samples.

Products Covered:

  • Self-Testing Kits
  • Lab-Based Screening Kits
  • Point-of-Care (PoC) Devices
  • Other Products

Sample Types Covered:

  • Blood
  • Urine
  • Saliva
  • Nasal/Throat Swabs
  • Stool

Distribution Channels Covered:

  • Direct-to-Consumer (DTC)
  • E-commerce Platforms
  • Institutional Sales
  • Retail Pharmacies
  • Government Procurement

Applications Covered:

  • Infectious Disease Detection
  • Chronic Disease Monitoring
  • Cancer Screening
  • Genetic & Prenatal Testing
  • Lifestyle & Wellness Monitoring
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Users
  • Pharmacies & Retail Chains
  • NGOs & Public Health Programs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Accessible Diagnostics & Screening Kits Market, By Product

  • 5.1 Introduction
  • 5.2 Self-Testing Kits
    • 5.2.1 Pregnancy Tests
    • 5.2.2 Glucose Monitoring
    • 5.2.3 COVID-19 Rapid Tests
    • 5.2.4 HIV/STI Screening
  • 5.3 Lab-Based Screening Kits
    • 5.3.1 Molecular Diagnostic Kits
    • 5.3.2 Immunoassay Kits
    • 5.3.3 Genetic Screening Panels
  • 5.4 Point-of-Care (PoC) Devices
    • 5.4.1 Blood Analyzers
    • 5.4.2 Urine Analyzers
    • 5.4.3 Mobile Diagnostic Units
  • 5.5 Other Products

6 Global Accessible Diagnostics & Screening Kits Market, By Sample Type

  • 6.1 Introduction
  • 6.2 Blood
  • 6.3 Urine
  • 6.4 Saliva
  • 6.5 Nasal/Throat Swabs
  • 6.6 Stool

7 Global Accessible Diagnostics & Screening Kits Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct-to-Consumer (DTC)
  • 7.3 E-commerce Platforms
  • 7.4 Institutional Sales
  • 7.5 Retail Pharmacies
  • 7.6 Government Procurement

8 Global Accessible Diagnostics & Screening Kits Market, By Application

  • 8.1 Introduction
  • 8.2 Infectious Disease Detection
  • 8.3 Chronic Disease Monitoring
  • 8.4 Cancer Screening
  • 8.5 Genetic & Prenatal Testing
  • 8.6 Lifestyle & Wellness Monitoring
  • 8.7 Other Applications

9 Global Accessible Diagnostics & Screening Kits Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Home Users
  • 9.5 Pharmacies & Retail Chains
  • 9.6 NGOs & Public Health Programs
  • 9.7 Other End Users

10 Global Accessible Diagnostics & Screening Kits Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Siemens Healthineers
  • 12.2 Agappe Diagnostics
  • 12.3 GE HealthCare
  • 12.4 PerkinElmer
  • 12.5 Roche Diagnostics
  • 12.6 Agilent Technologies
  • 12.7 Danaher Corporation
  • 12.8 Hologic, Inc.
  • 12.9 Abbott Laboratories
  • 12.10 bioMerieux
  • 12.11 Thermo Fisher Scientific
  • 12.12 Quest Diagnostics
  • 12.13 Bio-Rad Laboratories
  • 12.14 Becton, Dickinson and Company (BD)
  • 12.15 QuidelOrtho Corporation

List of Tables

  • Table 1 Global Accessible Diagnostics & Screening Kits Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Accessible Diagnostics & Screening Kits Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Accessible Diagnostics & Screening Kits Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 4 Global Accessible Diagnostics & Screening Kits Market Outlook, By Pregnancy Tests (2024-2032) ($MN)
  • Table 5 Global Accessible Diagnostics & Screening Kits Market Outlook, By Glucose Monitoring (2024-2032) ($MN)
  • Table 6 Global Accessible Diagnostics & Screening Kits Market Outlook, By COVID-19 Rapid Tests (2024-2032) ($MN)
  • Table 7 Global Accessible Diagnostics & Screening Kits Market Outlook, By HIV/STI Screening (2024-2032) ($MN)
  • Table 8 Global Accessible Diagnostics & Screening Kits Market Outlook, By Lab-Based Screening Kits (2024-2032) ($MN)
  • Table 9 Global Accessible Diagnostics & Screening Kits Market Outlook, By Molecular Diagnostic Kits (2024-2032) ($MN)
  • Table 10 Global Accessible Diagnostics & Screening Kits Market Outlook, By Immunoassay Kits (2024-2032) ($MN)
  • Table 11 Global Accessible Diagnostics & Screening Kits Market Outlook, By Genetic Screening Panels (2024-2032) ($MN)
  • Table 12 Global Accessible Diagnostics & Screening Kits Market Outlook, By Point-of-Care (PoC) Devices (2024-2032) ($MN)
  • Table 13 Global Accessible Diagnostics & Screening Kits Market Outlook, By Blood Analyzers (2024-2032) ($MN)
  • Table 14 Global Accessible Diagnostics & Screening Kits Market Outlook, By Urine Analyzers (2024-2032) ($MN)
  • Table 15 Global Accessible Diagnostics & Screening Kits Market Outlook, By Mobile Diagnostic Units (2024-2032) ($MN)
  • Table 16 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 17 Global Accessible Diagnostics & Screening Kits Market Outlook, By Sample Type (2024-2032) ($MN)
  • Table 18 Global Accessible Diagnostics & Screening Kits Market Outlook, By Blood (2024-2032) ($MN)
  • Table 19 Global Accessible Diagnostics & Screening Kits Market Outlook, By Urine (2024-2032) ($MN)
  • Table 20 Global Accessible Diagnostics & Screening Kits Market Outlook, By Saliva (2024-2032) ($MN)
  • Table 21 Global Accessible Diagnostics & Screening Kits Market Outlook, By Nasal/Throat Swabs (2024-2032) ($MN)
  • Table 22 Global Accessible Diagnostics & Screening Kits Market Outlook, By Stool (2024-2032) ($MN)
  • Table 23 Global Accessible Diagnostics & Screening Kits Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 24 Global Accessible Diagnostics & Screening Kits Market Outlook, By Direct-to-Consumer (DTC) (2024-2032) ($MN)
  • Table 25 Global Accessible Diagnostics & Screening Kits Market Outlook, By E-commerce Platforms (2024-2032) ($MN)
  • Table 26 Global Accessible Diagnostics & Screening Kits Market Outlook, By Institutional Sales (2024-2032) ($MN)
  • Table 27 Global Accessible Diagnostics & Screening Kits Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 28 Global Accessible Diagnostics & Screening Kits Market Outlook, By Government Procurement (2024-2032) ($MN)
  • Table 29 Global Accessible Diagnostics & Screening Kits Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Accessible Diagnostics & Screening Kits Market Outlook, By Infectious Disease Detection (2024-2032) ($MN)
  • Table 31 Global Accessible Diagnostics & Screening Kits Market Outlook, By Chronic Disease Monitoring (2024-2032) ($MN)
  • Table 32 Global Accessible Diagnostics & Screening Kits Market Outlook, By Cancer Screening (2024-2032) ($MN)
  • Table 33 Global Accessible Diagnostics & Screening Kits Market Outlook, By Genetic & Prenatal Testing (2024-2032) ($MN)
  • Table 34 Global Accessible Diagnostics & Screening Kits Market Outlook, By Lifestyle & Wellness Monitoring (2024-2032) ($MN)
  • Table 35 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 36 Global Accessible Diagnostics & Screening Kits Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 Global Accessible Diagnostics & Screening Kits Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 38 Global Accessible Diagnostics & Screening Kits Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 39 Global Accessible Diagnostics & Screening Kits Market Outlook, By Home Users (2024-2032) ($MN)
  • Table 40 Global Accessible Diagnostics & Screening Kits Market Outlook, By Pharmacies & Retail Chains (2024-2032) ($MN)
  • Table 41 Global Accessible Diagnostics & Screening Kits Market Outlook, By NGOs & Public Health Programs (2024-2032) ($MN)
  • Table 42 Global Accessible Diagnostics & Screening Kits Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.